In this video from Motley Fool Live, recorded on April 5, Fool.com Contributors Brian Orelli and Keith Speights discuss a question from a member named Angel, who asks whether Viatris (NASDAQ: VTRS) is worth holding. The duo discuss Viatris' prospects and the type of investor that is most appropriate for holding the generic-drug maker. Keith Speights: Is Viatris, the ticker there's VTRS, a keeper.
Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting